EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Changes in mean corpuscular volume after erythropoiesis-stimulating agent treatment are associated with renal outcomes in non-dialysis-dependent chronic kidney disease

Raku Son, Takuya Fujimaru, Tatsuo Kagimura, Tadashi Sofue, Takao Masaki, Masaaki Nakayama, Ichiei Narita

Clinical and Experimental Nephrology · 2026

DOI: 10.1007/s10157-026-02818-9 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical and Experimental Nephrology, 2026. Verfasst von Raku Son und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, St. Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo, 104-8560, Japan. Hauptthemen laut MEDLINE: Hematinics, Renal Insufficiency, Chronic, Darbepoetin alfa, Erythrocyte Indices. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kyowa Kirin.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mean corpuscular volume (MCV) is routinely measured in patients with chronic kidney disease (CKD) and anemia; however, its prognostic significance, particularly in the context of erythropoiesis-stimulating agent (ESA) therapy, remains unclear.

Methods

We conducted a post hoc analysis of the BRIGHTEN study, a multicenter, prospective trial that enrolled 1219 ESA-naïve patients with non-dialysis-dependent CKD who initiated darbepoetin alfa. Patients were categorized based on changes in MCV from baseline to week 16 as either increased or decreased. The primary outcome was renal function decline, defined as the initiation of dialysis, kidney transplantation, ≥ 50% reduction in estimated glomerular filtration rate (eGFR), or an eGFR ≤ 6 mL/min/1.73 m 2 within 96 weeks.

Results

MCV decreased in 778 (63.8%) patients during the study period. Changes in MCV were not correlated with baseline MCV values or ESA responsiveness. Over a mean follow-up of 2.46 ± 0.78 years, renal function decline occurred in 304 (39.1%) and 140 (31.7%) patients in the decreased and increased MCV groups, respectively. After adjusting for age, sex, baseline eGFR, albumin, high-sensitivity CRP, proteinuria, ferritin, transferrin saturation and ESA responsiveness, increased MCV remained independently associated with a reduced risk of renal function decline (adjusted hazard ratio 0.67; 95% confidence interval 0.53–0.85; p < 0.001).

Conclusion

In ESA-naïve patients with non-dialysis-dependent CKD, an increase in MCV following ESA treatment was associated with a significantly lower risk of renal function decline. Monitoring MCV dynamics may serve as a simple, adjunctive tool for risk stratification and individualized CKD management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HematinicsRenal Insufficiency, ChronicDarbepoetin alfaErythrocyte IndicesAnemiaKidneyHumansFemaleGlomerular Filtration RateMaleTreatment OutcomeMiddle AgedProspective StudiesAgedRenal DialysisTime FactorsRisk FactorsKidney Transplantation

Stichwörter der Autor:innen

Chronic kidney disease (CKD)ErythropoietinMean corpuscular volume

Substanzen

HematinicsDarbepoetin alfa

Autor:innen und Institutionen

  • Department of Nephrology, St. Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo, 104-8560, Japan.
  • Department of Nephrology, St. Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo, 104-8560, Japan. fujitaku@luke.ac.jp.
  • Foundation for Biomedical Research and Innovation at Kobe, Kobe, Japan.
  • Department of Cardiorenal and Cerebrovascular Medicine, Kagawa University, Kagawa, Japan.
  • Department of Nephrology, Hiroshima University Hospital, Hiroshima, Japan.
  • Division of Clinical Nephrology and Rheumatology, Kidney Research Center, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Förderung

  • Kyowa Kirin

Zitieren

APA

Son, R., Fujimaru, T., Kagimura, T., Sofue, T., Masaki, T., Nakayama, M., & Narita, I. (2026). Changes in mean corpuscular volume after erythropoiesis-stimulating agent treatment are associated with renal outcomes in non-dialysis-dependent chronic kidney disease. Clinical and Experimental Nephrology. https://doi.org/10.1007/s10157-026-02818-9

Vancouver

Son R, Fujimaru T, Kagimura T, Sofue T, Masaki T, Nakayama M, et al. Changes in mean corpuscular volume after erythropoiesis-stimulating agent treatment are associated with renal outcomes in non-dialysis-dependent chronic kidney disease. Clinical and Experimental Nephrology. 2026. doi:10.1007/s10157-026-02818-9

BibTeX
@article{Son2026,
  author = {Son, Raku and Fujimaru, Takuya and Kagimura, Tatsuo and Sofue, Tadashi and Masaki, Takao and Nakayama, Masaaki and Narita, Ichiei},
  title = {Changes in mean corpuscular volume after erythropoiesis-stimulating agent treatment are associated with renal outcomes in non-dialysis-dependent chronic kidney disease},
  journal = {Clinical and Experimental Nephrology},
  year = {2026},
  doi = {10.1007/s10157-026-02818-9}
}
Kostenlos starten →